Hims & Hers Health (NYSE:HIMS) Trading Down 4.1% Following Insider Selling

Hims & Hers Health, Inc. (NYSE:HIMS)’s share price traded down 4.1% on Tuesday after an insider sold shares in the company. The stock traded as low as $47.36 and last traded at $47.93. 11,177,873 shares were traded during trading, a decline of 67% from the average session volume of 34,156,691 shares. The stock had previously closed at $49.98.

Specifically, insider Soleil Boughton sold 2,572 shares of the stock in a transaction on Monday, August 11th. The stock was sold at an average price of $51.64, for a total transaction of $132,818.08. Following the sale, the insider directly owned 153,021 shares in the company, valued at approximately $7,902,004.44. This trade represents a 1.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 660,000 shares of the stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $50.58, for a total value of $33,382,800.00. Following the sale, the chief executive officer owned 2,214,769 shares in the company, valued at approximately $112,023,016.02. This represents a 22.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 60,000 shares of the stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the sale, the insider directly owned 169,940 shares in the company, valued at approximately $9,105,385.20. This trade represents a 26.09% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Analysts Set New Price Targets

Several analysts have commented on the company. Bank of America increased their target price on Hims & Hers Health from $22.00 to $26.00 and gave the company an “underperform” rating in a research note on Tuesday, April 29th. Citigroup restated a “sell” rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Needham & Company LLC restated a “hold” rating on shares of Hims & Hers Health in a research note on Tuesday, August 5th. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Finally, Truist Financial raised their price target on Hims & Hers Health from $45.00 to $48.00 and gave the stock a “hold” rating in a research note on Thursday, July 17th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health has an average rating of “Hold” and an average target price of $39.83.

Hims & Hers Health Trading Down 4.2%

The stock has a fifty day moving average of $53.39 and a 200 day moving average of $45.30. The company has a market capitalization of $10.72 billion, a P/E ratio of 59.85, a PEG ratio of 3.16 and a beta of 2.08. The company has a debt-to-equity ratio of 1.72, a quick ratio of 4.46 and a current ratio of 4.98.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). Hims & Hers Health had a net margin of 9.63% and a return on equity of 26.26%. The business had revenue of $544.83 million for the quarter, compared to the consensus estimate of $550.06 million. During the same period in the prior year, the business earned $0.06 earnings per share. Hims & Hers Health’s revenue was up 72.6% compared to the same quarter last year. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Trading of Hims & Hers Health

Institutional investors have recently made changes to their positions in the business. Quaker Wealth Management LLC purchased a new stake in shares of Hims & Hers Health during the second quarter worth about $29,000. Bessemer Group Inc. grew its position in shares of Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after purchasing an additional 312 shares in the last quarter. Spire Wealth Management purchased a new stake in shares of Hims & Hers Health during the second quarter worth about $42,000. Webster Bank N. A. grew its position in shares of Hims & Hers Health by 229.1% during the second quarter. Webster Bank N. A. now owns 905 shares of the company’s stock worth $45,000 after purchasing an additional 630 shares in the last quarter. Finally, Geneos Wealth Management Inc. bought a new stake in shares of Hims & Hers Health in the first quarter worth about $30,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.